Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14015897 | 0.83 | USP14 (0.32) | USP14 | |
| SCHEMBL20161659 | 0.78 | MGAM (0.38) | — | |
| SCHEMBL25713253 | 0.72 | KDM4E (0.40) | USP14PARP14 | |
| SCHEMBL12442952 | 0.68 | EPHX1 (0.41) | PARP14 | |
| SCHEMBL25281461 | 0.68 | HTR4 (0.39) | USP14PARP14 | |
| SCHEMBL25272072 | 0.67 | GSK3B (0.40) | — | |
| SCHEMBL2607204 | 0.66 | NCF1 (0.41) | PARP14 | |
| SCHEMBL18595476 | 0.66 | POLB (0.40) | PARP14 | |
| SCHEMBL7332383 | 0.66 | HTR4 (0.43) | — | |
| SCHEMBL12788442 | 0.66 | KMT2A (0.37) | USP14PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | SELP, SELPLG, SELE | USP14 4358/4885PARP14 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.